Trader consensus on no new COVID variant of concern before 2027 at 85.5% reflects the absence of any World Health Organization designation of a novel Variant of Concern in recent months, despite routine genomic surveillance. Dominant lineages such as XFG (Stratus) have circulated for over a year without meeting elevated severity or immune-escape thresholds, while BA.3.2 (Cicada) remains a low-risk Variant Under Monitoring with limited dominance and constrained transmissibility. Seasonal case rises in the U.S., UK, and Europe stem from established subvariants rather than fresh threats, and vaccine updates targeting XFG for the 2026-2027 season further stabilize expectations. A rapid shift would require unexpected compensatory mutations in monitored strains within the narrow remaining timeframe.